Literature DB >> 21325097

The "new" marijuana.

Daina L Wells1, Carol A Ott.   

Abstract

Synthetic cannabinoid-induced toxicity is increasing in frequency across the US, with more than 1057 reported cases as of August 2010. There is a paucity of literature on synthetic cannabinoid toxicity; however, there are various reports of adverse effects including tachycardia, hypertension, tachypnea, chest pain, heart palpitations, hallucinations, racing thoughts, and seizures. While reports suggest that toxic symptoms last no longer than 3-4 hours, with no residual adverse effects in many cases, there is concern about serious acute and long-term toxicities. This article reviews the development, abuse, toxicity, treatment, and legal status of synthetic cannabinoids. It is important for health-care professionals to recognize and appropriately treat synthetic cannabinoid-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325097     DOI: 10.1345/aph.1P580

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  19 in total

Review 1.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

Review 2.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

3.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

4.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

5.  First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.

Authors:  David McQuade; Simon Hudson; Paul I Dargan; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2012-08-31       Impact factor: 2.953

Review 6.  Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.

Authors:  Vikas Khullar; Ankur Jain; Maryam Sattari
Journal:  J Gen Intern Med       Date:  2014-02-20       Impact factor: 5.128

7.  Ischemic stroke after use of the synthetic marijuana "spice".

Authors:  Melissa J Freeman; David Z Rose; Martin A Myers; Clifton L Gooch; Andrea C Bozeman; W Scott Burgin
Journal:  Neurology       Date:  2013-11-08       Impact factor: 9.910

8.  High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use.

Authors:  Sameir Alhadi; Anupama Tiwari; Rais Vohra; Roy Gerona; Janak Acharya; Kathryn Bilello
Journal:  J Med Toxicol       Date:  2013-06

9.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922

10.  Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.

Authors:  Erin E Bonar; Lisham Ashrafioun; Mark A Ilgen
Journal:  Drug Alcohol Depend       Date:  2014-07-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.